BLAINJECTIONINJECTABLE
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Mechanism of Action
Programmed Death Ligand-1 Antagonists
Pharmacologic Class:
Programmed Death Ligand-1 Blocker
Clinical Trials (1)
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
Started Apr 2019
18 enrolled
B-cell Non Hodgkin LymphomaRichter's Transformation